1
|
Wang D, Tan Z, Yang J, Li L, Li H, Zhang H, Liu H, Liu Y, Wang L, Li Q, Guo H. Perfluorooctane sulfonate promotes atherosclerosis by modulating M1 polarization of macrophages through the NF-κB pathway. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY 2023; 249:114384. [PMID: 36512850 DOI: 10.1016/j.ecoenv.2022.114384] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 11/27/2022] [Accepted: 12/01/2022] [Indexed: 06/17/2023]
Abstract
Perfluorooctane sulfonate (PFOS) is a widely used and distributed perfluorinated compounds and is reported to be harmful to cardiovascular health; however, the direct association between PFOS exposure and atherosclerosis and the underlying mechanisms remain unknown. Therefore, this study aimed to investigate the effects of PFOS exposure on the atherosclerosis progression and the underlying mechanisms. PFOS was administered through oral gavage to apolipoprotein E-deficient (ApoE-/-) mice for 12 weeks. PFOS exposure significantly increased pulse wave velocity (PWV) and intima-media thickness (IMT), increased aortic plaque burden and vulnerability, and elevated serum lipid and inflammatory cytokine levels. PFOS promoted aortic and RAW264.7 M1 macrophage polarization, which increased the secretion of nitric oxide synthase (iNOS) and pro-inflammatory factors (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], and interleukin-1β [IL-1β]), and suppressed M2 macrophage polarization, which decreased the expression of CD206, arginine I (Arg-1), and interleukin-10 (IL-10). Moreover, PFOS activated nuclear factor-kappa B (NF-κB) in the aorta and macrophages. BAY11-7082 was used to inhibit NF-κB-alleviated M1 macrophage polarization and the inflammatory response induced by PFOS in RAW264.7 macrophages. Our results are the first to reveal the acceleratory effect of PFOS on the atherosclerosis progression in ApoE-/- mice, which is associated with the NF-κB activation of macrophages to M1 polarization to induce inflammation.
Collapse
Affiliation(s)
- Dan Wang
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Zhenzhen Tan
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Jing Yang
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Longfei Li
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Haoran Li
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Huaxing Zhang
- Core Facilities and Centers, Hebei Medical University, Shijiazhuang, China
| | - Heqiong Liu
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Yi Liu
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China
| | - Lei Wang
- Department of Medicinal Chemistry, Hebei Medical University, Shijiazhuang, China
| | - Qian Li
- Department of Physiology, Hebei Medical University, Shijiazhuang, China.
| | - Huicai Guo
- Department of Toxicology, Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, China.
| |
Collapse
|
2
|
Seime T, van Wanrooij M, Karlöf E, Kronqvist M, Johansson S, Matic L, Gasser TC, Hedin U. Biomechanical Assessment of Macro-Calcification in Human Carotid Atherosclerosis and Its Impact on Smooth Muscle Cell Phenotype. Cells 2022; 11:3279. [PMID: 36291144 PMCID: PMC9600867 DOI: 10.3390/cells11203279] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 10/14/2022] [Accepted: 10/17/2022] [Indexed: 12/13/2023] Open
Abstract
Intimal calcification and vascular stiffening are predominant features of end-stage atherosclerosis. However, their role in atherosclerotic plaque instability and how the extent and spatial distribution of calcification influence plaque biology remain unclear. We recently showed that extensive macro calcification can be a stabilizing feature of late-stage human lesions, associated with a reacquisition of more differentiated properties of plaque smooth muscle cells (SMCs) and extracellular matrix (ECM) remodeling. Here, we hypothesized that biomechanical forces related to macro-calcification within plaques influence SMC phenotype and contribute to plaque stabilization. We generated a finite element modeling (FEM) pipeline to assess plaque tissue stretch based on image analysis of preoperative computed tomography angiography (CTA) of carotid atherosclerotic plaques to visualize calcification and soft tissues (lipids and extracellular matrix) within the lesions. Biomechanical stretch was significantly reduced in tissues in close proximity to macro calcification, while increased levels were observed within distant soft tissues. Applying this data to an in vitro stretch model on primary vascular SMCs revealed upregulation of typical markers for differentiated SMCs and contractility under low stretch conditions but also impeded SMC alignment. In contrast, high stretch conditions in combination with calcifying conditions induced SMC apoptosis. Our findings suggest that the load bearing capacities of macro calcifications influence SMC differentiation and survival and contribute to atherosclerotic plaque stabilization.
Collapse
Affiliation(s)
- Till Seime
- Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, 17164 Stockholm, Sweden
| | - Max van Wanrooij
- Solid Mechanics, School of Engineering Sciences, KTH Royal Institute of Technology, 10044 Stockholm, Sweden
| | - Eva Karlöf
- Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, 17164 Stockholm, Sweden
| | - Malin Kronqvist
- Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, 17164 Stockholm, Sweden
| | - Staffan Johansson
- Biochemistry & Cell & Tumor Biology, Department of Medical Biochemistry and Microbiology, Uppsala University, 75123 Uppsala, Sweden
| | - Ljubica Matic
- Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, 17164 Stockholm, Sweden
| | - T. Christian Gasser
- Solid Mechanics, School of Engineering Sciences, KTH Royal Institute of Technology, 10044 Stockholm, Sweden
| | - Ulf Hedin
- Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, 17164 Stockholm, Sweden
| |
Collapse
|
3
|
Yin Z, Zhang J, Xu S, Liu J, Xu Y, Yu J, Zhao M, Pan W, Wang M, Wan J. The role of semaphorins in cardiovascular diseases: Potential therapeutic targets and novel biomarkers. FASEB J 2022; 36:e22509. [PMID: 36063107 DOI: 10.1096/fj.202200844r] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 07/24/2022] [Accepted: 08/09/2022] [Indexed: 12/17/2022]
Abstract
Semaphorins (Semas), which belongs to the axonal guidance molecules, include 8 classes and could affect axon growth in the nervous system. Recently, semaphorins were found to regulate other pathophysiological processes, such as immune response, oncogenesis, tumor angiogenesis, and bone homeostasis, through binding with their plexin and neuropilin receptors. In this review, we summarized the detailed role of semaphorins and their receptors in the pathological progression of various cardiovascular diseases (CVDs), highlighting that semaphorins may be potential therapeutic targets and novel biomarkers for CVDs.
Collapse
Affiliation(s)
- Zheng Yin
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Jishou Zhang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Shuwan Xu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Jianfang Liu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Yao Xu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Junping Yu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Mengmeng Zhao
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Wei Pan
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Menglong Wang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| | - Jun Wan
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.,Cardiovascular Research Institute, Wuhan University, Wuhan, China.,Hubei Key Laboratory of Cardiology, Wuhan, China
| |
Collapse
|
4
|
Hou X, Dai H, Zheng Y. Circular RNA hsa_circ_0008896 accelerates atherosclerosis by promoting the proliferation, migration and invasion of vascular smooth muscle cells via hsa-miR-633/CDC20B (cell division cycle 20B) axis. Bioengineered 2022; 13:5987-5998. [PMID: 35212610 PMCID: PMC8973975 DOI: 10.1080/21655979.2022.2039467] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Circular RNAs, a class of circularly closed non-coding RNAs, play essential roles in the formation of atherosclerosis, which is a frequent cause of cardiovascular and cerebrovascular diseases. Although many circular RNAs are found to be involved in the progression of atherosclerosis, more circular RNA regulators still need to be identified, to improve the understanding of the regulatory networks of atherosclerosis. Here, we found that hsa_circ_0008896 was significantly up-regulated in both in vitro and in vivo atherosclerosis models, indicating hsa_circ_0008896 was involved in the progression of atherosclerosis. Further functional analyses confirmed that knockdown of hsa_circ_0008896 decreased proliferation, migration, and invasion of VSMCs. In addition, we conducted bioinformatics analysis and found that hsa-miR-633 could directly bind to hsa_circ_0008896, which was confirmed by RNA immune-precipitation (RIP) assays. Results of proliferation, migration, and invasion assays showed that hsa-miR-633 inhibitor reversed the si-circ_0008896 phenotypes, indicating that hsa_circ_0008896 functionally bound to hsa-miR-633. At last, combining bioinformatics and experimental analyses, we found the protein target of hsa_circ_0008896/hsa-miR-633, CDC20B (cell division cycle 20B). The expression level of CDC20B was regulated by hsa-miR-633, and knockdown of CDC20B decreased proliferation, migration, and invasion of VSMCs. Taken together, hsa_circ_0008896 regulated the expression of CDC20B by sponging hsa-miR-633, and then enhanced proliferation, migration, and invasion of VSMCs to promote the progression of atherosclerosis.
Collapse
Affiliation(s)
- Xumin Hou
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Huangdong Dai
- Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Yue Zheng
- Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| |
Collapse
|
5
|
Maida CD, Daidone M, Pacinella G, Norrito RL, Pinto A, Tuttolomondo A. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. Int J Mol Sci 2022; 23:ijms23042397. [PMID: 35216512 PMCID: PMC8877605 DOI: 10.3390/ijms23042397] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Revised: 02/15/2022] [Accepted: 02/19/2022] [Indexed: 12/12/2022] Open
Abstract
Diabetes mellitus is a comprehensive expression to identify a condition of chronic hyperglycemia whose causes derive from different metabolic disorders characterized by altered insulin secretion or faulty insulin effect on its targets or often both mechanisms. Diabetes and atherosclerosis are, from the point of view of cardio- and cerebrovascular risk, two complementary diseases. Beyond shared aspects such as inflammation and oxidative stress, there are multiple molecular mechanisms by which they feed off each other: chronic hyperglycemia and advanced glycosylation end-products (AGE) promote ‘accelerated atherosclerosis’ through the induction of endothelial damage and cellular dysfunction. These diseases impact the vascular system and, therefore, the risk of developing cardio- and cerebrovascular events is now evident, but the observation of this significant correlation has its roots in past decades. Cerebrovascular complications make diabetic patients 2–6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke, they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization, and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.
Collapse
Affiliation(s)
- Carlo Domenico Maida
- Molecular and Clinical Medicine PhD Programme, University of Palermo, 90127 Palermo, Italy; (C.D.M.); (A.T.)
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
| | - Mario Daidone
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
- Correspondence:
| | - Gaetano Pacinella
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
| | - Rosario Luca Norrito
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
| | - Antonio Pinto
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
| | - Antonino Tuttolomondo
- Molecular and Clinical Medicine PhD Programme, University of Palermo, 90127 Palermo, Italy; (C.D.M.); (A.T.)
- U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” (PROMISE), University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy; (G.P.); (R.L.N.); (A.P.)
| |
Collapse
|
6
|
Affiliation(s)
- Ulf Hedin
- Departments of Vascular Surgery and Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
7
|
Takahashi L, Ishigami T, Tomiyama H, Kato Y, Kikuchi H, Tasaki K, Yamashita J, Inoue S, Taguri M, Nagao T, Chikamori T, Ishikawa Y, Yokoyama U. Increased Plasma Levels of Myosin Heavy Chain 11 Is Associated with Atherosclerosis. J Clin Med 2021; 10:jcm10143155. [PMID: 34300321 PMCID: PMC8304775 DOI: 10.3390/jcm10143155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 07/13/2021] [Accepted: 07/14/2021] [Indexed: 11/16/2022] Open
Abstract
Many studies have revealed numerous potential biomarkers for atherosclerosis, but tissue-specific biomarkers are still needed. Recent lineage-tracing studies revealed that smooth muscle cells (SMCs) contribute substantially to plaque formation, and the loss of SMCs causes plaque vulnerability. We investigated the association of SMC-specific myosin heavy chain 11 (myosin-11) with atherosclerosis. Forty-five patients with atherosclerosis and 34 control subjects were recruited into our study. In the atherosclerosis patients, 35 patients had either coronary artery disease (CAD) or peripheral artery disease (PAD), and 10 had both CAD and PAD. Coronary arteries isolated from five patients were subjected to histological study. Circulating myosin-11 levels were higher in the CAD or PAD group than in controls. The area under the receiver operating characteristic curve of myosin-11 was 0.954. Circulating myosin-11 levels in the CAD and PAD group were higher than in the CAD or PAD group, while high-sensitivity C-reactive protein concentrations did not differ between these groups. Multinomial logistic regression analyses showed a significant association of myosin-11 levels with the presence of multiple atherosclerotic regions. Myosin-11 was expressed in the medial layer of human atherosclerotic lesions where apoptosis elevated. Circulating myosin-11 levels may be useful for detecting spatial expansion of atherosclerotic regions.
Collapse
Affiliation(s)
- Lisa Takahashi
- Department of Cardiology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (L.T.); (H.T.); (J.Y.); (T.C.)
- Department of Physiology, Tokyo Medical University, 6-6-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan;
| | - Tomoaki Ishigami
- Department of Cardio-Renal Medicine and Medical Science, Yokohama City University, 3-9 Fukuura, Yokohama 236-0004, Japan;
| | - Hirofumi Tomiyama
- Department of Cardiology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (L.T.); (H.T.); (J.Y.); (T.C.)
| | - Yuko Kato
- Department of Physiology, Tokyo Medical University, 6-6-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan;
| | - Hiroyuki Kikuchi
- Department of Preventive Medicine and Public Health, Tokyo Medical University, 6-6-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan; (H.K.); (S.I.)
| | - Koichiro Tasaki
- Department of Pathology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (K.T.); (T.N.)
| | - Jun Yamashita
- Department of Cardiology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (L.T.); (H.T.); (J.Y.); (T.C.)
| | - Shigeru Inoue
- Department of Preventive Medicine and Public Health, Tokyo Medical University, 6-6-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan; (H.K.); (S.I.)
| | - Masataka Taguri
- Department of Data Science, Yokohama City University, 22-2 Seto, Kanazawa-ku, Yokohama 236-0027, Japan;
| | - Toshitaka Nagao
- Department of Pathology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (K.T.); (T.N.)
| | - Taishiro Chikamori
- Department of Cardiology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; (L.T.); (H.T.); (J.Y.); (T.C.)
| | - Yoshihiro Ishikawa
- Cardiovascular Research Institute, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;
| | - Utako Yokoyama
- Department of Physiology, Tokyo Medical University, 6-6-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan;
- Cardiovascular Research Institute, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;
- Correspondence: ; Tel.: +81-03-351-6141
| |
Collapse
|
8
|
Esobi IC, Barksdale C, Heard-Tate C, Powell RR, Bruce TF, Stamatikos A. MOVAS Cells: A Versatile Cell Line for Studying Vascular Smooth Muscle Cell Cholesterol Metabolism. Lipids 2021; 56:413-422. [PMID: 33881166 PMCID: PMC8928454 DOI: 10.1002/lipd.12303] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 03/25/2021] [Accepted: 03/26/2021] [Indexed: 12/31/2022]
Abstract
Cholesterol metabolism is paramount to cells. Aberrations to cholesterol metabolism affects cholesterol homeostasis, which may impact the risk of several diseases. Recent evidence has suggested that vascular smooth muscle cell (VSMC) cholesterol metabolism may play a role in atherosclerosis. However, there is scant in vitro mechanistic data involving primary VSMC that directly tests how VSMC cholesterol metabolism may impact atherosclerosis. One reason for this lack of data is due to the impracticality of gene manipulation studies in primary VSMC, as cultured primary VSMC become senescent and lose their morphology rapidly. However, there are no immortalized VSMC lines known to be suitable for studying VSMC cholesterol metabolism. The purpose of this study was to determine whether MOVAS cells, a commercially available VSMC line, are suitable to use for studying VSMC cholesterol metabolism. Using immunoblotting and immunofluorescence, we showed that MOVAS cells express ABCA1, ABCG1, and SREBP-2. We also determined that MOVAS cells efflux cholesterol to apoAI and HDL, which indicates functionality of ABCA1/ABCG1. In serum-starved MOVAS cells, SREBP-2 target gene expression was increased, confirming SREBP-2 functionality. We detected miR-33a expression in MOVAS cells and determined this microRNA can silence ABCA1 and ABCG1 via identifying conserved miR-33a binding sites within ABCA1/ABCG1 3'UTR in MOVAS cells. We showed that cholesterol-loading MOVAS cells results in this cell line to transdifferentiate into a macrophage-like cell, which also occurs when VSMC accumulate cholesterol. Our characterization of MOVAS cells sufficiently demonstrates that they are suitable to use for studying VSMC cholesterol metabolism in the context of atherosclerosis.
Collapse
Affiliation(s)
| | | | - Caterra Heard-Tate
- Department of Food, Nutrition, and Packaging Sciences, Clemson University
| | | | | | - Alexis Stamatikos
- Department of Food, Nutrition, and Packaging Sciences, Clemson University
| |
Collapse
|
9
|
Rickel AP, Sanyour HJ, Leyda NA, Hong Z. Extracellular Matrix Proteins and Substrate Stiffness Synergistically Regulate Vascular Smooth Muscle Cell Migration and Cortical Cytoskeleton Organization. ACS APPLIED BIO MATERIALS 2020; 3:2360-2369. [PMID: 34327310 PMCID: PMC8318011 DOI: 10.1021/acsabm.0c00100] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Vascular smooth muscle cell (VSMC) migration is a critical step in the progression of cardiovascular disease and aging. Migrating VSMCs encounter a highly heterogeneous environment with the varying extracellular matrix (ECM) composition due to the differential synthesis of collagen and fibronectin (FN) in different regions and greatly changing stiffness, ranging from the soft necrotic core of plaques to hard calcifications within blood vessel walls. In this study, we demonstrate an application of a two-dimensional (2D) model consisting of an elastically tunable polyacrylamide gel of varying stiffness and ECM protein coating to study VSMC migration. This model mimics the in vivo microenvironment that VSMCs experience within a blood vessel wall, which may help identify potential therapeutic targets for the treatment of atherosclerosis. We found that substrate stiffness had differential effects on VSMC migration on type 1 collagen (COL1) and FN-coated substrates. VSMCs on COL1-coated substrates showed significantly diminished migration distance on stiffer substrates, while on FN-coated substrates VSMCs had significantly increased migration distance. In addition, cortical stress fiber orientation increased in VSMCs cultured on more rigid COL1-coated substrates, while decreasing on stiffer FN-coated substrates. On both proteins, a more disorganized cytoskeletal architecture was associated with faster migration. Overall, these results demonstrate that different ECM proteins can cause substrate stiffness to have differential effects on VSMC migration in the progression of cardiovascular diseases and aging.
Collapse
Affiliation(s)
- Alex P Rickel
- Department of Biomedical Engineering, University of South Dakota, Sioux Falls, South Dakota 57107, United States; BIOSNTR, Sioux Falls, South Dakota 57107, United States
| | - Hanna J Sanyour
- Department of Biomedical Engineering, University of South Dakota, Sioux Falls, South Dakota 57107, United States; BIOSNTR, Sioux Falls, South Dakota 57107, United States
| | - Neil A Leyda
- Department of Chemical Engineering, South Dakota School of Mines & Technology, Rapid City, South Dakota 57701, United States
| | - Zhongkui Hong
- Department of Biomedical Engineering, University of South Dakota, Sioux Falls, South Dakota 57107, United States; BIOSNTR, Sioux Falls, South Dakota 57107, United States
| |
Collapse
|
10
|
Umahara T, Uchihara T, Hirao K, Shimizu S, Hashimoto T, Kohno M, Hanyu H. Essential autophagic protein Beclin 1 localizes to atherosclerotic lesions of human carotid and major intracranial arteries. J Neurol Sci 2020; 414:116836. [PMID: 32344218 DOI: 10.1016/j.jns.2020.116836] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 03/23/2020] [Accepted: 04/12/2020] [Indexed: 01/23/2023]
Abstract
Macrophage autophagy has been shown to exert a protective role in atherosclerosis. Beclin 1 is an essential autophagic protein, and the Beclin-1-interacting complex promotes the formation of autophagosomes. However, the localization of Beclin 1 in human atherosclerotic lesions has not been clarified to date. We hence investigated the immunolocalization of Beclin 1 in atherosclerotic lesions of human carotid and major intracranial arteries. Furthermore, we investigated the colocalization of Beclin 1 with the 14-3-3 eta isoform and high mobility group box 1 (HMGB1). Beclin 1 was observed in the cytoplasm of many foamy macrophages located near to or in the periphery of lipid-rich necrotic cores. Beclin 1 colocalized with the 14-3-3 eta isoform in carotid plaques, and also colocalized with HMGB1 in carotid plaques. This is the first demonstration of Beclin 1 immunolocalization in human carotid and main cerebral artery plaques. We believe that our results will contribute towards understanding the role of autophagy in atherosclerosis and towards the prevention of stroke.
Collapse
Affiliation(s)
- Takahiko Umahara
- Department of Neurology, Mizuno Memorial Rehabilitation Hospital, 5-5-5 Nishiarai, Adachi-ku, Tokyo 123-0848, Japan; Departments of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
| | - Toshiki Uchihara
- Neurology Clinic with Neuromorphomics Laboratory, Nitobe-Memorial Nakano General Hospital, Tokyo 164-8607, Japan
| | - Kentaro Hirao
- Departments of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - Soichiro Shimizu
- Departments of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - Takao Hashimoto
- Departments of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - Michihiro Kohno
- Departments of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - Haruo Hanyu
- Departments of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| |
Collapse
|
11
|
Orenstein JM. An ultrastructural pathologist's views on fibroblasts, modified smooth muscle cells, wound healing, stenosing arteriopathies, Kawasaki disease, Dupuytren's contracture, and the stroma of carcinomas. Ultrastruct Pathol 2020; 44:2-14. [PMID: 32154752 DOI: 10.1080/01913123.2019.1704332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
It wasn't until 1960 that the dense bodies of the peripheral actin arrays of fibroblasts were finally visualized, i.e., stress fibers (SFs). Mistakenly assumed that its SFs turned the fibroblast into a unique cell situated somewhere in a continuum between it and a smooth muscle cell (SMC), it was descriptively named a "myofibroblast" (MF). Automatically, spindle cells with SFs and/or smooth muscle actin by SMA IHC-staining, became MFs, although endothelial cells, pericytes, modified SMCs (mSMC), and myoepithelial cells all contain SFs. An invisible "intermediate" cell was hypothesized to exist somewhere between SMA-negative and positive fibroblasts, and named a "proto-myofibroblast". The sub-epithelial spindle cells of normal and malignant tumors of the GI, GU, and respiratory tracts are all fibroblasts with SFs. The second erroneous myofibroblast came from a 1971 rat wound healing study and its 1974 human counterpart. Updated analysis of the papers' TEMs proved that the cells are mSMCs and not fibroblasts (AKA: MFs). The pathognomonic cells of Dupuytren's contracture are mSMCs and fibroblasts and that of the stenosing arteriopathy of Kawasaki Disease and other similar arteriopathies are mSMCs. TEM remains a powerful tool.
Collapse
|
12
|
Rykaczewska U, Suur BE, Röhl S, Razuvaev A, Lengquist M, Sabater-Lleal M, van der Laan SW, Miller CL, Wirka RC, Kronqvist M, Gonzalez Diez M, Vesterlund M, Gillgren P, Odeberg J, Lindeman JH, Veglia F, Humphries SE, de Faire U, Baldassarre D, Tremoli E, Lehtiö J, Hansson GK, Paulsson-Berne G, Pasterkamp G, Quertermous T, Hamsten A, Eriksson P, Hedin U, Matic L. PCSK6 Is a Key Protease in the Control of Smooth Muscle Cell Function in Vascular Remodeling. Circ Res 2020; 126:571-585. [PMID: 31893970 DOI: 10.1161/circresaha.119.316063] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
RATIONALE PCSKs (Proprotein convertase subtilisins/kexins) are a protease family with unknown functions in vasculature. Previously, we demonstrated PCSK6 upregulation in human atherosclerotic plaques associated with smooth muscle cells (SMCs), inflammation, extracellular matrix remodeling, and mitogens. OBJECTIVE Here, we applied a systems biology approach to gain deeper insights into the PCSK6 role in normal and diseased vessel wall. METHODS AND RESULTS Genetic analyses revealed association of intronic PCSK6 variant rs1531817 with maximum internal carotid intima-media thickness progression in high-cardiovascular risk subjects. This variant was linked with PCSK6 mRNA expression in healthy aortas and plaques but also with overall plaque SMA+ cell content and pericyte fraction. Increased PCSK6 expression was found in several independent human cohorts comparing atherosclerotic lesions versus healthy arteries, using transcriptomic and proteomic datasets. By immunohistochemistry, PCSK6 was localized to fibrous cap SMA+ cells and neovessels in plaques. In human, rat, and mouse intimal hyperplasia, PCSK6 was expressed by proliferating SMA+ cells and upregulated after 5 days in rat carotid balloon injury model, with positive correlation to PDGFB (platelet-derived growth factor subunit B) and MMP (matrix metalloprotease) 2/MMP14. Here, PCSK6 was shown to colocalize and cointeract with MMP2/MMP14 by in situ proximity ligation assay. Microarrays of carotid arteries from Pcsk6-/- versus control mice revealed suppression of contractile SMC markers, extracellular matrix remodeling enzymes, and cytokines/receptors. Pcsk6-/- mice showed reduced intimal hyperplasia response upon carotid ligation in vivo, accompanied by decreased MMP14 activation and impaired SMC outgrowth from aortic rings ex vivo. PCSK6 silencing in human SMCs in vitro leads to downregulation of contractile markers and increase in MMP2 expression. Conversely, PCSK6 overexpression increased PDGFBB (platelet-derived growth factor BB)-induced cell proliferation and particularly migration. CONCLUSIONS PCSK6 is a novel protease that induces SMC migration in response to PDGFB, mechanistically via modulation of contractile markers and MMP14 activation. This study establishes PCSK6 as a key regulator of SMC function in vascular remodeling. Visual Overview: An online visual overview is available for this article.
Collapse
Affiliation(s)
- Urszula Rykaczewska
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Bianca E Suur
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Samuel Röhl
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Anton Razuvaev
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Mariette Lengquist
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Maria Sabater-Lleal
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.).,Unit of Genomics of Complex Diseases, Institut de Recerca Hospital de Sant Pau (IIB-Sant Pau), Barcelona, Spain (M.S.-L.)
| | - Sander W van der Laan
- Central Diagnostics Laboratory, Laboratories, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, Utrecht University, The Netherlands (S.v.d.L.)
| | - Clint L Miller
- Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville (C.L.M.).,Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (C.L.M., R.C.W., T.Q.)
| | - Robert C Wirka
- Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (C.L.M., R.C.W., T.Q.)
| | - Malin Kronqvist
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Maria Gonzalez Diez
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.)
| | - Mattias Vesterlund
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Sweden (M.V., J.L.)
| | - Peter Gillgren
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, and Department of Vascular Surgery, Södersjukhuset, Stockholm, Sweden (P.G.)
| | - Jacob Odeberg
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.).,Science for Life Laboratory, Department of Proteomics, School of Chemistry Biotechnology and Health (CBH), KTH, Stockholm, Sweden (J.O.)
| | - Jan H Lindeman
- Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Fabrizio Veglia
- Centro Cardiologico Monzino, IRCCS, Milan, Italy (F.V., D.B., E.T.)
| | - Steve E Humphries
- Cardiovascular Genetics, Institute Cardiovascular Science, University College of London, Department of Medicine, Rayne Building, United Kingdom (S.E.H.)
| | - Ulf de Faire
- Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden (H.d.F.)
| | - Damiano Baldassarre
- Centro Cardiologico Monzino, IRCCS, Milan, Italy (F.V., D.B., E.T.).,Department of Medical Biotechnology and Translational Medicine, Università di Milano, Milan, Italy (D.B.)
| | - Elena Tremoli
- Centro Cardiologico Monzino, IRCCS, Milan, Italy (F.V., D.B., E.T.)
| | | | - Janne Lehtiö
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Sweden (M.V., J.L.)
| | - Göran K Hansson
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.)
| | - Gabrielle Paulsson-Berne
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.)
| | - Gerard Pasterkamp
- Laboratory of Experimental Cardiology, Division Heart & Lungs, University Medical Center Utrecht, The Netherlands (G.P.)
| | - Thomas Quertermous
- Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (C.L.M., R.C.W., T.Q.)
| | - Anders Hamsten
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.)
| | - Per Eriksson
- Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (M.S.-L., M.G.D., G.P.-B., G.K.H., A.H., P.E., J.O.)
| | - Ulf Hedin
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| | - Ljubica Matic
- From the Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden (U.R., B.E.S., S.R., A.R., M.L., M.K., U.H., L.M.)
| |
Collapse
|
13
|
Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol 2019; 16:727-744. [PMID: 31243391 DOI: 10.1038/s41569-019-0227-9] [Citation(s) in RCA: 582] [Impact Index Per Article: 116.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/23/2019] [Indexed: 02/08/2023]
Abstract
Vascular smooth muscle cells (VSMCs) are a major cell type present at all stages of an atherosclerotic plaque. According to the 'response to injury' and 'vulnerable plaque' hypotheses, contractile VSMCs recruited from the media undergo phenotypic conversion to proliferative synthetic cells that generate extracellular matrix to form the fibrous cap and hence stabilize plaques. However, lineage-tracing studies have highlighted flaws in the interpretation of former studies, revealing that these studies had underestimated both the content and functions of VSMCs in plaques and have thus challenged our view on the role of VSMCs in atherosclerosis. VSMCs are more plastic than previously recognized and can adopt alternative phenotypes, including phenotypes resembling foam cells, macrophages, mesenchymal stem cells and osteochondrogenic cells, which could contribute both positively and negatively to disease progression. In this Review, we present the evidence for VSMC plasticity and summarize the roles of VSMCs and VSMC-derived cells in atherosclerotic plaque development and progression. Correct attribution and spatiotemporal resolution of clinically beneficial and detrimental processes will underpin the success of any therapeutic intervention aimed at VSMCs and their derivatives.
Collapse
Affiliation(s)
- Gemma L Basatemur
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Helle F Jørgensen
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Murray C H Clarke
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Martin R Bennett
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Ziad Mallat
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.
- INSERM U970, Paris Cardiovascular Research Center, Paris, France.
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
14
|
Umahara T, Uchihara T, Hirao K, Shimizu S, Hashimoto T, Akimoto J, Kohno M, Hanyu H. Frontotemporal dementia-associated protein "phosphorylated TDP-43" localizes to atherosclerotic lesions of human carotid and main cerebral arteries. Histol Histopathol 2019; 35:159-167. [PMID: 31259382 DOI: 10.14670/hh-18-140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The transactivation response DNA binding protein (TARDP) of 43 kDa (TDP-43) is a nuclear protein pivotal in RNA processing. Because phosphorylated (p) TDP-43 has been identified as a component of ubiquitin-positive and tau-negative inclusions in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), it is considered to play a major role in neurodegenerative processes. We investigated the immunolocalization of pTDP-43 in atherosclerotic lesions of human carotid and main cerebral arteries. Furthermore, we investigated the co-localization between pTDP-43 and 14-3-3 eta isoform or high mobility group box 1 (HMGB1). pTDP-43 localized in the cytoplasm of many foamy macrophages located in the periphery of lipid-rich necrotic cores, and in the cytoplasm of infiltrated smooth muscle cell-like cells. pTDP-43 co-localized the 14-3-3 eta isoform in carotid plaques. pTDP-43 also co-localized HMGB1. This is the first demonstration of pTDP-43 immunolocalization in human carotid and main cerebral artery plaques. We believe that demonstration of the localization of pTDP-43 in atherosclerotic lesions is important as this may contribute to the establishment of the clinical diagnostic imaging of FTLD and ALS using the pTDP-43 epitope. Moreover, this finding may be useful for further understanding the role of TDP in cell death.
Collapse
Affiliation(s)
- Takahiko Umahara
- Department of Neurology, Mizuno Memorial Rehabilitation Hospital, Nisharai, Adachi-ku, Tokyo, Japan. .,Department of Geriatric Medicine, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan.,Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Toshiki Uchihara
- Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.,Neurology Clinic and Neuromorphomics Laboratory, Nitobe-Memorial Nakano General Hospital, Tokyo, Japan
| | - Kentaro Hirao
- Department of Geriatric Medicine, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| | - Soichiro Shimizu
- Department of Geriatric Medicine, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| | - Takao Hashimoto
- Department of Neurosurgery, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| | - Jiro Akimoto
- Department of Neurosurgery, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| | - Michihiro Kohno
- Department of Neurosurgery, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| | - Haruo Hanyu
- Department of Geriatric Medicine, Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
| |
Collapse
|
15
|
Moss ME, DuPont JJ, Iyer SL, McGraw AP, Jaffe IZ. No Significant Role for Smooth Muscle Cell Mineralocorticoid Receptors in Atherosclerosis in the Apolipoprotein-E Knockout Mouse Model. Front Cardiovasc Med 2018; 5:81. [PMID: 30038907 PMCID: PMC6046374 DOI: 10.3389/fcvm.2018.00081] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 06/11/2018] [Indexed: 12/12/2022] Open
Abstract
Objective: Elevated levels of the hormone aldosterone are associated with increased risk of myocardial infarction and stroke in humans and increased progression and inflammation of atherosclerotic plaques in animal models. Aldosterone acts through the mineralocorticoid receptor (MR) which is expressed in vascular smooth muscle cells (SMCs) where it promotes SMC calcification and chemokine secretion in vitro. The objective of this study is to explore the role of the MR specifically in SMCs in the progression of atherosclerosis and the associated vascular inflammation in vivo in the apolipoprotein E knockout (ApoE−/−) mouse model. Methods and Results: Male ApoE−/− mice were bred with mice in which MR could be deleted specifically from SMCs by tamoxifen injection. The resulting atheroprone SMC-MR-KO mice were compared to their MR-Intact littermates after high fat diet (HFD) feeding for 8 or 16 weeks or normal diet for 12 months. Body weight, tail cuff blood pressure, heart and spleen weight, and serum levels of glucose, cholesterol, and aldosterone were measured for all mice at the end of the treatment period. Serial histologic sections of the aortic root were stained with Oil Red O to assess plaque size, lipid content, and necrotic core area; with PicroSirius Red for quantification of collagen content; by immunofluorescent staining with anti-Mac2/Galectin-3 and anti-smooth muscle α-actin antibodies to assess inflammation and SMC marker expression; and with Von Kossa stain to detect plaque calcification. In the 16-week HFD study, these analyses were also performed in sections from the brachiocephalic artery. Flow cytometry of cell suspensions derived from the aortic arch was also performed to quantify vascular inflammation after 8 and 16 weeks of HFD. Deletion of the MR specifically from SMCs did not significantly change plaque size, lipid content, necrotic core, collagen content, inflammatory staining, actin staining, or calcification, nor were there differences in the extent of vascular inflammation between MR-Intact and SMC-MR-KO mice in the three experiments. Conclusion: SMC-MR does not directly contribute to the formation, progression, or inflammation of atherosclerotic plaques in the ApoE−/− mouse model of atherosclerosis. This indicates that the MR in non-SMCs mediates the pro-atherogenic effects of MR activation.
Collapse
Affiliation(s)
- M Elizabeth Moss
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States.,Department of Developmental, Molecular, and Chemical Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States
| | - Jennifer J DuPont
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States
| | - Surabhi L Iyer
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States
| | - Adam P McGraw
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States
| | - Iris Z Jaffe
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United States.,Department of Developmental, Molecular, and Chemical Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States
| |
Collapse
|
16
|
Goikuria H, Freijo MDM, Vega Manrique R, Sastre M, Elizagaray E, Lorenzo A, Vandenbroeck K, Alloza I. Characterization of Carotid Smooth Muscle Cells during Phenotypic Transition. Cells 2018; 7:cells7030023. [PMID: 29562638 PMCID: PMC5870355 DOI: 10.3390/cells7030023] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Revised: 03/02/2018] [Accepted: 03/15/2018] [Indexed: 02/07/2023] Open
Abstract
Vascular smooth muscle cells (VSMCs) are central players in carotid atherosclerosis plaque development. Although the precise mechanisms involved in plaque destabilization are not completely understood, it is known that VSMC proliferation and migration participate in plaque stabilization. In this study, we analyzed expression patterns of genes involved in carotid atherosclerosis development (e.g., transcription factors of regulation of SMC genes) of VSMCs located inside or outside the plaque lesion that may give clues about changes in phenotypic plasticity during atherosclerosis. VSMCs were isolated from 39 carotid plaques extracted from symptomatic and asymptomatic patients by endarterectomy. Specific biomarker expression, related with VSMC phenotype, was analyzed by qPCR, western immunoblot, and confocal microscopy. MYH11, CNN1, SRF, MKL2, and CALD1 were significantly underexpressed in VSMCs from plaques compared with VSMCs from a macroscopically intact (MIT) region, while SPP1, KLF4, MAPLC3B, CD68, and LGALS3 were found significantly upregulated in plaque VSMCs versus MIT VSMCs. The gene expression pattern of arterial VSMCs from a healthy donor treated with 7-ketocholesterol showed high similarity with the expression pattern of carotid plaque VSMCs. Our results indicate that VSMCs isolated from plaque show a typical SMC dedifferentiated phenotype with macrophage-like features compared with VSMCs isolated from a MIT region of the carotid artery. Additionally, MYH11, KLF5, and SPP1 expression patterns were found to be associated with symptomatology of human carotid atherosclerosis.
Collapse
Affiliation(s)
- Haize Goikuria
- Neurogenomiks Neuroscience Department, Faculty of Medicine and Nursing, Basque Country University, 48940 Leioa, Spain.
- ACHUCARRO Basque Center for Neuroscience, Basque Country University, 48940 Leioa, Spain.
| | | | | | - María Sastre
- Neurogenomiks Neuroscience Department, Faculty of Medicine and Nursing, Basque Country University, 48940 Leioa, Spain.
- ACHUCARRO Basque Center for Neuroscience, Basque Country University, 48940 Leioa, Spain.
| | | | - Ana Lorenzo
- Neurology Unit, Basurto University Hospital (BUH), 48013 Bilbao, Spain.
| | - Koen Vandenbroeck
- Neurogenomiks Neuroscience Department, Faculty of Medicine and Nursing, Basque Country University, 48940 Leioa, Spain.
- ACHUCARRO Basque Center for Neuroscience, Basque Country University, 48940 Leioa, Spain.
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.
| | - Iraide Alloza
- Neurogenomiks Neuroscience Department, Faculty of Medicine and Nursing, Basque Country University, 48940 Leioa, Spain.
- ACHUCARRO Basque Center for Neuroscience, Basque Country University, 48940 Leioa, Spain.
- IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.
| |
Collapse
|
17
|
Leszczynska A, Murphy JM. Vascular Calcification: Is it rather a Stem/Progenitor Cells Driven Phenomenon? Front Bioeng Biotechnol 2018; 6:10. [PMID: 29479528 PMCID: PMC5811524 DOI: 10.3389/fbioe.2018.00010] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 01/22/2018] [Indexed: 12/21/2022] Open
Abstract
Vascular calcification (VC) has witnessed a surge of interest. Vasculature is virtually an omnipresent organ and has a notably high capacity for repair throughout embryonic and adult life. Of the vascular diseases, atherosclerosis is a leading cause of morbidity and mortality on account of ectopic cartilage and bone formation. Despite the identification of a number of risk factors, all the current theories explaining pathogenesis of VC in atherosclerosis are far from complete. The most widely accepted response to injury theory and smooth muscle transdifferentiation to explain the VC observed in atherosclerosis is being challenged. Recent focus on circulating and resident progenitor cells in the vasculature and their role in atherogenesis and VC has been the driving force behind this review. This review discusses intrinsic cellular players contributing to fate determination of cells and tissues to form ectopic cartilage and bone formation.
Collapse
Affiliation(s)
- Aleksandra Leszczynska
- Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| | - J Mary Murphy
- Regenerative Medicine Institute, National University of Ireland Galway, Galway, Ireland
| |
Collapse
|
18
|
Halak S, Östling G, Edsfeldt A, Kennbäck C, Dencker M, Gonçalves I, Asciutto G. Spotty Carotid Plaques Are Associated with Inflammation and the Occurrence of Cerebrovascular Symptoms. Cerebrovasc Dis Extra 2018; 8:16-25. [PMID: 29402768 PMCID: PMC5836198 DOI: 10.1159/000485258] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Accepted: 11/06/2017] [Indexed: 11/19/2022] Open
Abstract
Background Echolucent carotid plaques have been related to an increased risk of ischemic cerebrovascular events. The aim of the present study was to evaluate whether a new objective ultrasonographic parameter, the statistical geometric feature (SGF), reflecting spottiness of carotid plaques, can be associated with cerebrovascular symptoms and with a rupture-prone plaque phenotype. Methods The plaques of 144 patients who underwent carotid endarterectomy were included in this study. SGF and plaque area were estimated by outlining the plaque on ultrasound (US) images. The correlation coefficient for inter- and intraobserver variability was 0.69 and 0.93, respectively. The SGF values were normalized to the degree of stenosis (SGF/DS). The plaques collected at surgery 1 day after the US were analyzed histologically, and inflammatory markers and matrix metalloproteinases (MMPs) were measured. Results Patients with ipsilateral hemispheric symptoms had higher SGF/DS compared to patients without symptoms (0.82 [0.59–1.16] vs. 0.70 [0.56–0.89], p = 0.01). Analysis of plaque components revealed a positive correlation between SGF/DS and the percentage of the plaque area stained for lipids, macrophages, and hemorrhage. A correlation was also found between SGF/DS and plaque expression of interleukin-6, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, vascular endothelial growth factor A, C-C motif chemokine 3 and 20, and MMP-9. An inverse correlation was found with plaque levels of osteoprotegerin. Conclusions The present study supports the concept that spottiness is a feature of the carotid plaques rich in inflammation and can be associated with the typical phenotype of high-risk plaques.
Collapse
Affiliation(s)
- Sanela Halak
- Department of Medical Imaging and Physiology, Skåne University Hospital, Malmö, Sweden
| | - Gerd Östling
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Andreas Edsfeldt
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.,Department of Cardiology, Skåne University Hospital, Malmö, Sweden
| | - Cecilia Kennbäck
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Magnus Dencker
- Department of Medical Imaging and Physiology, Skåne University Hospital, Malmö, Sweden
| | - Isabel Gonçalves
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.,Department of Cardiology, Skåne University Hospital, Malmö, Sweden
| | - Giuseppe Asciutto
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.,Vascular Center, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
19
|
Zuo P, Zuo Z, Zheng Y, Wang X, Zhou Q, Chen L, Ma G. Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice. Front Pharmacol 2017; 8:647. [PMID: 28959204 PMCID: PMC5603739 DOI: 10.3389/fphar.2017.00647] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Accepted: 08/31/2017] [Indexed: 01/06/2023] Open
Abstract
Inflammatory mechanisms are involved in the process of atherosclerotic plaque formation and rupture. Accumulating evidence suggests that protease-activated receptor (PAR)-2 contributes to the pathophysiology of chronic inflammation on the vasculature. To directly examine the role of PAR-2 in atherosclerosis, we generated apolipoprotein E/PAR-2 double-deficient mice. Mice were fed with high-fat diet for 12 weeks starting at ages of 6 weeks. PAR-2 deficiency attenuated atherosclerotic lesion progression with reduced total lesion area, reduced percentage of stenosis and reduced total necrotic core area. PAR-2 deficiency increased fibrous cap thickness and collagen content of plaque. Moreover, PAR-2 deficiency decreased smooth muscle cell content, macrophage accumulation, matrix metallopeptidase-9 expression and neovascularization in plaque. Relative quantitative PCR assay using thoracic aorta revealed that PAR-2 deficiency reduced mRNA expression of inflammatory molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1. In vitro experiment, we found that PAR-2 deficiency reduced mRNA expression of interferon-γ, interleukin-6, TNF-α and MCP-1 in macrophage under unstimulated and lipopolysaccharide-stimulated conditions. These results suggest that PAR-2 deficiency attenuates the progression and instability of atherosclerotic plaque.
Collapse
Affiliation(s)
- Pengfei Zuo
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Zhi Zuo
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Yueyue Zheng
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Xin Wang
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Qianxing Zhou
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Long Chen
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| | - Genshan Ma
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityNanjing, China
| |
Collapse
|
20
|
Roles of Cells from the Arterial Vessel Wall in Atherosclerosis. Mediators Inflamm 2017; 2017:8135934. [PMID: 28680196 PMCID: PMC5478858 DOI: 10.1155/2017/8135934] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 04/26/2017] [Accepted: 05/02/2017] [Indexed: 02/07/2023] Open
Abstract
Atherosclerosis has been identified as a chronic inflammatory disease of the arterial vessel wall. Accumulating evidence indicates that different cells from the tunica intima, media, adventitia, and perivascular adipose tissue not only comprise the intact and normal arterial vessel wall but also participate all in the inflammatory response of atherosclerosis via multiple intricate pathways. For instance, endothelial dysfunction has historically been considered to be the initiator of the development of atherosclerosis. The migration and proliferation of smooth muscle cells also play a pivotal role in the progression of atherosclerosis. Additionally, the fibroblasts from the adventitia and adipocytes from perivascular adipose tissue have received considerable attention given their special functions that contribute to atherosclerosis. In addition, numerous types of cytokines produced by different cells from the arterial vessel wall, including endothelium-derived relaxing factors, endothelium-derived contracting factors, tumor necrosis factors, interleukin, adhesion molecules, interferon, and adventitium-derived relaxing factors, have been implicated in atherosclerosis. Herein, we summarize the possible roles of different cells from the entire arterial vessel wall in the pathogenesis of atherosclerosis.
Collapse
|
21
|
von Scheidt M, Zhao Y, Kurt Z, Pan C, Zeng L, Yang X, Schunkert H, Lusis AJ. Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis. Cell Metab 2017; 25:248-261. [PMID: 27916529 PMCID: PMC5484632 DOI: 10.1016/j.cmet.2016.11.001] [Citation(s) in RCA: 139] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/26/2016] [Accepted: 11/03/2016] [Indexed: 12/13/2022]
Abstract
Most of the biological understanding of mechanisms underlying coronary artery disease (CAD) derives from studies of mouse models. The identification of multiple CAD loci and strong candidate genes in large human genome-wide association studies (GWASs) presented an opportunity to examine the relevance of mouse models for the human disease. We comprehensively reviewed the mouse literature, including 827 literature-derived genes, and compared it to human data. First, we observed striking concordance of risk factors for atherosclerosis in mice and humans. Second, there was highly significant overlap of mouse genes with human genes identified by GWASs. In particular, of the 46 genes with strong association signals in CAD GWASs that were studied in mouse models, all but one exhibited consistent effects on atherosclerosis-related phenotypes. Third, we compared 178 CAD-associated pathways derived from human GWASs with 263 from mouse studies and observed that the majority were consistent between the species.
Collapse
Affiliation(s)
- Moritz von Scheidt
- Deutsches Herzzentrum München, Technische Universität München, 80333 Munich, Germany
| | - Yuqi Zhao
- Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Zeyneb Kurt
- Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Calvin Pan
- Departments of Medicine, Microbiology, and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Lingyao Zeng
- Deutsches Herzzentrum München, Technische Universität München, 80333 Munich, Germany
| | - Xia Yang
- Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Heribert Schunkert
- Deutsches Herzzentrum München, Technische Universität München, 80333 Munich, Germany; Deutsches Zentrum für Herz- und Kreislauferkrankungen (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany
| | - Aldons J Lusis
- Departments of Medicine, Microbiology, and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
| |
Collapse
|
22
|
Ma YD, Thiyagarajan V, Tsai MJ, Lue SI, Chia YC, Shyue SK, Weng CF. Pyrogallol abates VSMC migration via modulation of Caveolin-1, matrix metalloproteinase and intima hyperplasia in carotid ligation mouse. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2016; 48:63-75. [PMID: 27768988 DOI: 10.1016/j.etap.2016.10.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Revised: 10/07/2016] [Accepted: 10/08/2016] [Indexed: 06/06/2023]
Abstract
Migration of vascular smooth muscle cells (VSMCs) contributes to intimal hyperplasia and other vascular diseases. Caveolin-1 (Cav-1) has been recognized as a proliferative inhibitor of VSMCs and is likely to be an important regulator of VSMC migration. The underlying mechanism of pyrogallol on the VSMC migration is not fully understood. This study attempted to dissect the role of Cav-1 and matrix metalloproteinase (MMP) in VSMC migration and to investigate the effect of pyrogallol on VSMC mobility during carotid artery ligation mice. The mRNA expression of MMP-3 and MMP-13 was down-regulated in cultured VSMC prepared from Cav-1-deficient (Cav-1 KO) mice whereas MMP-14 expression was up-regulated. Pyrogallol effectively inhibited the migration of Cav-1 KO VSMC by promoting the expression of tissue inhibitors of metalloproteinase (TIMP)-2. Pyrogallol also inhibited the migration of Cav-1 wild type (WT) VSMC, however, by increasing TIMP-1 expression and repressing MMP-2 activity. In a parallel in vivo study, intra-peritoneal (ip) of pyrogallol to carotid artery ligated mice significantly suppressed intima formation in mice carotid artery. Furthermore, the proMMP-9 activity in pyrogallol-treated mice serum significantly increased from Day 0 to Day 2 and decreased from Day 2 to Day 7 in a time-dependent manner. In addition, WT mice treated with pyrogallol had significantly reduced neointima formation, whereas no differences were observed in Cav-1 knock out (KO) mice. These results suggest that pyrogallol not only inhibited VSMC migration but also effectively diminishes the severity of neointima hyperplasia, implying that pyrogallol possesses potential anti-atherogenic effects for the treatment of vascular diseases.
Collapse
Affiliation(s)
- Yu-Dong Ma
- Department of Life Science and the Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan
| | - Varadharajan Thiyagarajan
- Department of Life Science and the Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan
| | - May-Jywan Tsai
- Neural Regeneration Laboratory, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei 11221, Taiwan
| | - Sheng-I Lue
- Department of Life Science and the Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan
| | - Yi-Chen Chia
- Department of Food Science & Technology, Tajen University, Ping Tung Hsien, Taiwan
| | - Song-Kun Shyue
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Ching-Feng Weng
- Department of Life Science and the Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan.
| |
Collapse
|
23
|
Perisic Matic L, Rykaczewska U, Razuvaev A, Sabater-Lleal M, Lengquist M, Miller CL, Ericsson I, Röhl S, Kronqvist M, Aldi S, Magné J, Paloschi V, Vesterlund M, Li Y, Jin H, Diez MG, Roy J, Baldassarre D, Veglia F, Humphries SE, de Faire U, Tremoli E, Odeberg J, Vukojević V, Lehtiö J, Maegdefessel L, Ehrenborg E, Paulsson-Berne G, Hansson GK, Lindeman JHN, Eriksson P, Quertermous T, Hamsten A, Hedin U. Phenotypic Modulation of Smooth Muscle Cells in Atherosclerosis Is Associated With Downregulation of LMOD1, SYNPO2, PDLIM7, PLN, and SYNM. Arterioscler Thromb Vasc Biol 2016; 36:1947-61. [PMID: 27470516 DOI: 10.1161/atvbaha.116.307893] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Accepted: 07/12/2016] [Indexed: 01/08/2023]
Abstract
OBJECTIVE Key augmented processes in atherosclerosis have been identified, whereas less is known about downregulated pathways. Here, we applied a systems biology approach to examine suppressed molecular signatures, with the hypothesis that they may provide insight into mechanisms contributing to plaque stability. APPROACH AND RESULTS Muscle contraction, muscle development, and actin cytoskeleton were the most downregulated pathways (false discovery rate=6.99e-21, 1.66e-6, 2.54e-10, respectively) in microarrays from human carotid plaques (n=177) versus healthy arteries (n=15). In addition to typical smooth muscle cell (SMC) markers, these pathways also encompassed cytoskeleton-related genes previously not associated with atherosclerosis. SYNPO2, SYNM, LMOD1, PDLIM7, and PLN expression positively correlated to typical SMC markers in plaques (Pearson r>0.6, P<0.0001) and in rat intimal hyperplasia (r>0.8, P<0.0001). By immunohistochemistry, the proteins were expressed in SMCs in normal vessels, but largely absent in human plaques and intimal hyperplasia. Subcellularly, most proteins localized to the cytoskeleton in cultured SMCs and were regulated by active enhancer histone modification H3K27ac by chromatin immunoprecipitation-sequencing. Functionally, the genes were downregulated by PDGFB (platelet-derived growth factor beta) and IFNg (interferron gamma), exposure to shear flow stress, and oxLDL (oxidized low-density lipoprotein) loading. Genetic variants in PDLIM7, PLN, and SYNPO2 loci associated with progression of carotid intima-media thickness in high-risk subjects without symptoms of cardiovascular disease (n=3378). By eQTL (expression quantitative trait locus), rs11746443 also associated with PDLIM7 expression in plaques. Mechanistically, silencing of PDLIM7 in vitro led to downregulation of SMC markers and disruption of the actin cytoskeleton, decreased cell spreading, and increased proliferation. CONCLUSIONS We identified a panel of genes that reflect the altered phenotype of SMCs in vascular disease and could be early sensitive markers of SMC dedifferentiation.
Collapse
Affiliation(s)
- Ljubica Perisic Matic
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.).
| | - Urszula Rykaczewska
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Anton Razuvaev
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Maria Sabater-Lleal
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Mariette Lengquist
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Clint L Miller
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Ida Ericsson
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Samuel Röhl
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Malin Kronqvist
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Silvia Aldi
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Joelle Magné
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Valentina Paloschi
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Mattias Vesterlund
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Yuhuang Li
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Hong Jin
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Maria Gonzalez Diez
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Joy Roy
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Damiano Baldassarre
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Fabrizio Veglia
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Steve E Humphries
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Ulf de Faire
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Elena Tremoli
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Jacob Odeberg
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Vladana Vukojević
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Janne Lehtiö
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Lars Maegdefessel
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Ewa Ehrenborg
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Gabrielle Paulsson-Berne
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Göran K Hansson
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Jan H N Lindeman
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Per Eriksson
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Thomas Quertermous
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Anders Hamsten
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| | - Ulf Hedin
- From the Departments of Molecular Medicine and Surgery (L.P.M., U.R., A.R., M.L., I.E., S.R., M.K., S.A., J.R., U.H.), Medicine (M.S.-L., J.M., V.P., Y.L., H.J., M.G.D., L.M., E.E., G.P.-B., G.K.H., P.E., A.H.), Division of Cardiovascular Epidemiology, Institute of Environmental Medicine (U.d.F.), and Department of Clinical Neuroscience, Center for Molecular Medicine (V.V.), Karolinska Institutet, Solna, Sweden; Division of Vascular Surgery, Stanford University, CA (C.L.M., T.Q.); Science for Life Laboratory, Solna, Sweden (M.V., J.L.); Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Italy (D.B., E.T.); Dipartimento di Scienze Cliniche e di Comunità, Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.B., F.V., E.T.); British Heart Foundation Laboratories, Department of Medicine, University College of London, United Kingdom (S.E.H.); Department of Cardiology, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden (U.d.F.); Science for Life Laboratory, Department of Proteomics, Stockholm, Sweden (J.O.); and Department of Vascular Surgery, Leiden University Medical Center, The Netherlands (J.H.N.L.)
| |
Collapse
|
24
|
Edsfeldt A, Dunér P, Ståhlman M, Mollet IG, Asciutto G, Grufman H, Nitulescu M, Persson AF, Fisher RM, Melander O, Orho-Melander M, Borén J, Nilsson J, Gonçalves I. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. Arterioscler Thromb Vasc Biol 2016; 36:1132-40. [DOI: 10.1161/atvbaha.116.305675] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Accepted: 03/23/2016] [Indexed: 11/16/2022]
Affiliation(s)
- Andreas Edsfeldt
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Pontus Dunér
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Marcus Ståhlman
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Ines G. Mollet
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Giuseppe Asciutto
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Helena Grufman
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Mihaela Nitulescu
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Ana Flor Persson
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Rachel M. Fisher
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Olle Melander
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Marju Orho-Melander
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Jan Borén
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Jan Nilsson
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| | - Isabel Gonçalves
- From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J
| |
Collapse
|
25
|
Tan X, Gao J, Shi Z, Tai S, Chan LL, Yang Y, Peng DQ, Liao DF, Jiang ZS, Chang YZ, Gui Y, Zheng XL. MG132 Induces Expression of Monocyte Chemotactic Protein-Induced Protein 1 in Vascular Smooth Muscle Cells. J Cell Physiol 2016; 232:122-8. [PMID: 27035356 DOI: 10.1002/jcp.25396] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 03/29/2016] [Indexed: 11/07/2022]
Abstract
Monocyte chemoattractant protein-1 (MCP-1) has been reported to induce the expression of monocyte chemotactic protein-induced protein 1 (MCPIP1), which undergoes ubiquitination degradation. Therefore, we predict that in vascular smooth muscle (VSMCs), MCPIP1 may be induced by MCP-1 and undergo degradation, which can be inhibited by the proteasome inhibitor, MG132. Our results showed that treatment of human VSMCs with MCP-1 did not increase the expression of MCPIP1. Treatment with MG132, however, elevated MCPIP1 protein levels through stimulation of the gene transcription, but not through increasing protein stability. MCPIP1 expression induced by MG132 was inhibited by α-amanitin inhibition of gene transcription or cycloheximide inhibition of protein synthesis. Our further studies showed that MCPIP1 expression induced by MG132 was inhibited by the inhibitors of AKT and p38 kinase, suggesting a role of the AKT-p38 pathway in MG132 effects. We also found that treatment with MG132 induces apoptosis, but overexpression of MCPIP1 inhibited bromodeoxyuridine (BrdU) incorporation of human VSMCs without induction of significant apoptosis. In summary, MCPIP1 expression is induced by MG132 likely through activation of the AKT-p38 pathway. MCPIP1 inhibits SMC proliferation without induction of apoptosis. J. Cell. Physiol. 232: 122-128, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Xi Tan
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Division of Stem Cell Regulation and Application, State Key Laboratory of Chinese Medicine Powder and Medicine Innovation in Hunan (Incubation), Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Jie Gao
- Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada
| | - Zhan Shi
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Shi Tai
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Leona Loretta Chan
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Yang Yang
- Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Dao-Quan Peng
- Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Duan-Fang Liao
- Division of Stem Cell Regulation and Application, State Key Laboratory of Chinese Medicine Powder and Medicine Innovation in Hunan (Incubation), Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Zhi-Sheng Jiang
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Institute of Cardiovascular Disease and Key Lab for Arteriosclerogy of Hunan Province, University of South China, Hengyang, Hunan, China
| | - Ying-Zi Chang
- Department of Pharmacology, A. T. Still University, Kirksville College of Osteopathic Medicine, Kirksville, Missouri
| | - Yu Gui
- Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada
| | - Xi-Long Zheng
- Department of Biochemistry and Molecular Biology, Smooth Muscle Research Group, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
| |
Collapse
|
26
|
Kim S, Lee MW, Kim TS, Song JW, Nam HS, Cho HS, Jang SJ, Ryu J, Oh DJ, Gweon DG, Park SH, Park K, Oh WY, Yoo H, Kim JW. Intracoronary dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular imaging with a clinical dose of indocyanine green for the assessment of high-risk plaques and stent-associated inflammation in a beating coronary artery. Eur Heart J 2016; 37:2833-2844. [PMID: 26787442 DOI: 10.1093/eurheartj/ehv726] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 10/19/2015] [Accepted: 12/10/2015] [Indexed: 01/22/2023] Open
Abstract
AIMS Inflammation plays essential role in development of plaque disruption and coronary stent-associated complications. This study aimed to examine whether intracoronary dual-modal optical coherence tomography (OCT)-near-infrared fluorescence (NIRF) structural-molecular imaging with indocyanine green (ICG) can estimate inflammation in swine coronary artery. METHODS AND RESULTS After administration of clinically approved NIRF-enhancing ICG (2.0 mg/kg) or saline, rapid coronary imaging (20 mm/s pullback speed) using a fully integrated OCT-NIRF catheter was safely performed in 12 atheromatous Yucatan minipigs and in 7 drug-eluting stent (DES)-implanted Yorkshire pigs. Stronger NIRF activity was identified in OCT-proven high-risk plaque compared to normal or saline-injected controls (P = 0.0016), which was validated on ex vivo fluorescence reflectance imaging. In vivo plaque target-to-background ratio (pTBR) was much higher in inflamed lipid-rich plaque compared to fibrous plaque (P < 0.0001). In vivo and ex vivo peak pTBRs correlated significantly (P < 0.0022). In vitro cellular ICG uptake and histological validations corroborated the OCT-NIRF findings in vivo. Indocyanine green colocalization with macrophages and lipids of human plaques was confirmed with autopsy atheroma specimens. Two weeks after DES deployment, OCT-NIRF imaging detected strong NIRF signals along stent struts, which was significantly higher than baseline (P = 0.0156). Histologically, NIRF signals in peri-strut tissue co-localized well with macrophages. CONCLUSION The OCT-NIRF imaging with a clinical dose of ICG was feasible to accurately assess plaque inflammation and DES-related inflammation in a beating coronary artery. This highly translatable dual-modal molecular-structural imaging strategy could be relevant for clinical intracoronary estimation of high-risk plaques and DES biology.
Collapse
Affiliation(s)
- Sunwon Kim
- Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea
| | - Min Woo Lee
- Department of Biomedical Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea
| | - Tae Shik Kim
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Joon Woo Song
- Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea
| | - Hyeong Soo Nam
- Department of Biomedical Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea
| | - Han Saem Cho
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Sun-Joo Jang
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Jiheun Ryu
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Dong Joo Oh
- Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea
| | - Dae-Gab Gweon
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Seong Hwan Park
- Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea.,Department of Legal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
| | - Kyeongsoon Park
- Division of Bioimaging, Chuncheon Center, Korea Basic Science Institute, Daejeon, Republic of Korea
| | - Wang-Yuhl Oh
- Department of Mechanical Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Hongki Yoo
- Department of Biomedical Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea
| | - Jin Won Kim
- Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-703, Republic of Korea
| |
Collapse
|
27
|
Edsfeldt A, Gonçalves I, Grufman H, Nitulescu M, Dunér P, Bengtsson E, Mollet IG, Persson A, Nilsson M, Orho-Melander M, Melander O, Björkbacka H, Nilsson J. Impaired Fibrous Repair. Arterioscler Thromb Vasc Biol 2014; 34:2143-50. [DOI: 10.1161/atvbaha.114.303414] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Diabetes mellitus (DM) type II is increasing rapidly worldwide. Patients with DM II have a greater atherosclerotic burden and higher risk of developing cardiovascular complications. Inflammation has been proposed as the main cause for the high risk of atherosclerotic disease in DM II. In this study, we compared markers of inflammation and fibrous repair in plaques from subjects with and without DM II.
Approach and Results—
Carotid endarterectomy specimens were obtained from 63 patients with and 131 without DM. Plaque structure, connective tissue proteins, inflammatory cells, and markers were analyzed by immunohistochemistry, ELISA, Mesoscale, and Luminex technology. Carotid plaques from diabetics had lower levels of extracellular matrix proteins, elastin, and collagen, which are critical for plaque stability. Plaques from diabetics had reduced levels of platelet-derived growth factor and matrix metalloproteinase-2, both important for tissue repair. No differences were observed in inflammatory markers in plaques from diabetic and nondiabetic patients.
Conclusion—
This study suggests that atherosclerotic plaques in subjects with DM II are more prone to rupture because of impaired repair responses rather than to increased vascular inflammation. Although this study did not have a mechanistic design, our findings suggest that targeting impaired repair responses in carotid plaques may help to increase our understanding of atherosclerotic plaque development and vulnerability in patients with DM II.
Collapse
Affiliation(s)
- Andreas Edsfeldt
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Isabel Gonçalves
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Helena Grufman
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Mihaela Nitulescu
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Pontus Dunér
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Eva Bengtsson
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Inês G. Mollet
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Ana Persson
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Marie Nilsson
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Marju Orho-Melander
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Olle Melander
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Harry Björkbacka
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| | - Jan Nilsson
- From the Experimental Cardiovascular Research Unit (A.E., I.G., H.G., M.N., P.D., E.B., A.P., M.N., H.B., J.N.) and Department of Clinical Sciences (I.G.M., M.O.-M., O.M.), Clinical Research Center, Clinical Sciences, Lund University, Malmö, Sweden; and Department of Cardiology—Coronary Diseases, Skåne University Hospital, Malmö, Sweden (A.E., I.G., H.G., A.P., M.N.)
| |
Collapse
|
28
|
Zhang N, Xie X, Chen H, Chen H, Yu H, Wang JA. Stem cell-based therapies for atherosclerosis: perspectives and ongoing controversies. Stem Cells Dev 2014; 23:1731-40. [PMID: 24702267 DOI: 10.1089/scd.2014.0078] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Atherosclerosis is a major contributor to life-threatening cardiovascular events, the leading cause of death worldwide. Since the mechanisms of atherosclerosis have not been fully understood, currently, there are no effective approaches to regressing atherosclerosis. Therefore, there is a dire need to explore the mechanisms and potential therapeutic strategies to prevent or reverse the progression of atherosclerosis. In recent years, stem cell-based therapies have held promises to various diseases, including atherosclerosis. Unfortunately, the efficacy of stem cell-based therapies for atherosclerosis as reported in the literature has been inconsistent or even conflicting. In this review, we summarize the current literature of stem cell-based therapies for atherosclerosis and discuss possible mechanisms and future directions of these potential therapies.
Collapse
Affiliation(s)
- Na Zhang
- 1 Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou, China
| | | | | | | | | | | |
Collapse
|
29
|
Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques. Redox Biol 2014; 2:642-50. [PMID: 24936437 PMCID: PMC4052526 DOI: 10.1016/j.redox.2014.04.004] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 04/12/2014] [Accepted: 04/13/2014] [Indexed: 11/23/2022] Open
Abstract
Plaque instability associated with acute coronary syndromes results in part from apoptosis and senescence of cells within the atherosclerotic (AS) lesion. Increased cellular oxidative stress has been proposed to contribute to plaque progression and changes in composition, leading to plaque instability. Our objective was to examine the role of NADPH oxidase in smooth muscle cell (SMC) phenotypes associated with an unstable plaque. Aortae were isolated from pre-lesion (8 weeks of age) and post-lesion (35 weeks of age) hypercholesterolemic mice (ApoE(-/-)/LDLR(-/-), AS), and age-matched normal C57BL/6J mice. We observed an age-dependent increase in reactive oxygen species (ROS) in aorta from AS mice, with evidence for elevated ROS prior to lesion development. Whereas macrophage infiltration was restricted to the lesion, oxidized lipids extended beyond the plaque and into the vessel wall. Consistent with these findings, we observed dynamic changes in the expression of NADPH oxidases in AS vessels. Specifically, Nox1 expression was increased early and decreased with lesion progression, while induction of Nox4 was a late event. Nox2 and p22(phox) were elevated throughout lesion development. Similar to observations in aortae, SMCs isolated from the lesion of AS aortae had decreased Nox1 and increased Nox4 levels as compared to SMCs from normal mice. AS SMCs demonstrated increased generation of ROS, cell cycle arrest, evidence of senescence, and increased susceptibility to apoptosis. Overexpression of Nox4 in normal SMCs recapitulated the phenotypes of the AS SMCs. We conclude that increased expression of Nox4 in AS may drive SMC phenotypes that lead to the plaque instability and rupture responsible for myocardial infarction and stroke.
Collapse
|
30
|
Lin YC, Chen LH, Varadharajan T, Tsai MJ, Chia YC, Yuan TC, Sung PJ, Weng CF. Resveratrol inhibits glucose-induced migration of vascular smooth muscle cells mediated by focal adhesion kinase. Mol Nutr Food Res 2014; 58:1389-401. [PMID: 24659233 DOI: 10.1002/mnfr.201300698] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Revised: 01/21/2014] [Accepted: 02/06/2014] [Indexed: 11/10/2022]
Abstract
SCOPE Diabetes is a critical factor for atherosclerosis, as hyperglycemia induces vascular smooth muscle cell (VSMC) proliferation and migration and subsequently contributes to the formation of atherosclerotic lesions. This study investigates whether resveratrol plays a regulatory role in the proliferation and migration of VSMCs under high glucose induction to imitate a hyperglycemic condition. METHODS AND RESULTS Resveratrol inhibited the migration of VSMCs in the wound-healing assay and the formation of lamellipodia and filopodia as assessed by atomic force microscopy scanning. Resveratrol suppressed the mRNA expression of c-Src, Rac1, cdc42, IRS-1, MEKK1, MEKK4, and mitogen-activated protein kinase along with the protein levels of c-Src, p-Src, and cdc42 in VSMCs. Resveratrol decreased the level of p-FAK protein under normal glucose conditions. Resveratrol could inhibit the activities of matrix metalloproteinase (MMP) 2 and MMP 9 as shown by zymography. Moreover, resveratrol also regulated the mitogen-activated protein kinase pathway and MMP activities of VSMC migration under the high glucose condition. CONCLUSION The antimigratory effects of resveratrol by reduced MMP expression through the inhibition of Rac1, p-FAK, and lamellipodia formation and the activation of p-AKT and p-ERK1/2 suggest that resveratrol is a potential compound for the treatment of vascular diseases via the regulation of VSMC migration.
Collapse
Affiliation(s)
- Yi-Chiao Lin
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Perivascular delivery of Notch 1 siRNA inhibits injury-induced arterial remodeling. PLoS One 2014; 9:e84122. [PMID: 24416200 PMCID: PMC3885538 DOI: 10.1371/journal.pone.0084122] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Accepted: 11/12/2013] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVES To determine the efficacy of perivascular delivery of Notch 1 siRNA in preventing injury-induced arterial remodeling. METHODS AND RESULTS Carotid artery ligation was performed to induce arterial remodeling. After 14 days, morphometric analysis confirmed increased vSMC growth and subsequent media thickening and neointimal formation. Laser capture microdissection, quantitative qRT-PCR and immunoblot analysis of medial tissue revealed a significant increase in Notch1 receptor and notch target gene, Hrt 1 and 2 expression in the injured vessels. Perivascular delivery of Notch 1 siRNA by pluronic gel inhibited the injury-induced increase in Notch 1 receptor and target gene expression when compared to scrambled siRNA controls while concomitantly reducing media thickening and neointimal formation to pre-injury, sham-operated levels. Selective Notch 1 knockdown also reversed the injury-induced inhibition of pro-apoptotic Bax expression while decreasing injury-induced anti-apoptotic Bcl-XL expression to sham-operated control levels. In parallel experiments, proliferative cyclin levels, as measured by PCNA expression, were reversed to sham-operated control levels following selective Notch 1 knockdown. CONCLUSION These results suggest that injury-induced arterial remodeling can be successfully inhibited by localized perivascular delivery of Notch 1 siRNA.
Collapse
|
32
|
Fahim A, Crooks MG, Morice AH, Hart SP. Increased platelet binding to circulating monocytes in idiopathic pulmonary fibrosis. Lung 2014; 192:277-84. [PMID: 24395126 DOI: 10.1007/s00408-013-9546-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Accepted: 12/14/2013] [Indexed: 10/25/2022]
Abstract
PURPOSE Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and its prognosis is poor. Epidemiological evidence suggests an association of IPF with vascular disease and thrombotic tendency, which may be related to platelet activation. METHODS Platelet-monocyte adhesion in peripheral blood was examined by flow cytometry in patients with IPF (n = 19), interstitial lung disease (ILD) other than IPF (n = 9), and control subjects without pulmonary fibrosis (n = 14). Expression of platelet activation markers P-selectin (CD62P), PSGL-1 (CD162), and CD40 ligand (CD40L) on leukocytes and platelets were studied. Plasma concentrations of soluble P-selectin and CD40L were measured by ELISA. RESULTS Significantly elevated levels of platelet-monocyte binding were found in patients with IPF (35.6 ± 4.34 % [mean ± SEM]) compared with patients with non-IPF ILD (23.5 ± 3.68 %) and non-ILD control subjects (16.5 ± 2.26 %; P < 0.01). There was a trend towards increased divalent cation-independent platelet-monocyte binding in IPF (6.0 ± 0.77 % [mean ± SEM]) compared with non-IPF ILD (4.3 ± 1.38 %) and control subjects without ILD (3.1 ± 1.75 %; P = 0.058). There was no differential surface expression of platelet activation markers on subsets of leukocytes or platelets. Plasma concentrations of CD40L and soluble P-selectin did not differ between IPF and control subjects. Platelet-monocyte binding had no significant correlation with percent predicted TLco or FVC. CONCLUSIONS Platelet-monocyte binding is increased in IPF, suggesting increased platelet activation. This conjugation is predominantly calcium-dependent, but there may be more calcium-independent adhesion in IPF. These findings support further research into the role of platelet activation in IPF.
Collapse
Affiliation(s)
- Ahmed Fahim
- Division of Cardiovascular and Respiratory Studies, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ, UK,
| | | | | | | |
Collapse
|
33
|
Beaufrère H. Atherosclerosis: Comparative Pathogenesis, Lipoprotein Metabolism, and Avian and Exotic Companion Mammal Models. J Exot Pet Med 2013. [DOI: 10.1053/j.jepm.2013.10.016] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
34
|
Bi Y, Zhong H, Xu K, Qi X. Combination of Periaortic Elastase Incubation and Cholesterol-Rich Diet: A Novel Model of Atherosclerosis in Rabbit Abdominal Aorta. Cell Biochem Biophys 2013; 68:611-4. [DOI: 10.1007/s12013-013-9753-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Connelly JJ, Cherepanova OA, Doss JF, Karaoli T, Lillard TS, Markunas CA, Nelson S, Wang T, Ellis PD, Langford CF, Haynes C, Seo DM, Goldschmidt-Clermont PJ, Shah SH, Kraus WE, Hauser ER, Gregory SG. Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis. Hum Mol Genet 2013; 22:5107-20. [PMID: 23912340 DOI: 10.1093/hmg/ddt365] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Smooth muscle cell (SMC) proliferation is a hallmark of vascular injury and disease. Global hypomethylation occurs during SMC proliferation in culture and in vivo during neointimal formation. Regardless of the programmed or stochastic nature of hypomethylation, identifying these changes is important in understanding vascular disease, as maintenance of a cells' epigenetic profile is essential for maintaining cellular phenotype. Global hypomethylation of proliferating aortic SMCs and concomitant decrease of DNMT1 expression were identified in culture during passage. An epigenome screen identified regions of the genome that were hypomethylated during proliferation and a region containing Collagen, type XV, alpha 1 (COL15A1) was selected by 'genomic convergence' for characterization. COL15A1 transcript and protein levels increased with passage-dependent decreases in DNA methylation and the transcript was sensitive to treatment with 5-Aza-2'-deoxycytidine, suggesting DNA methylation-mediated gene expression. Phenotypically, knockdown of COL15A1 increased SMC migration and decreased proliferation and Col15a1 expression was induced in an atherosclerotic lesion and localized to the atherosclerotic cap. A sequence variant in COL15A1 that is significantly associated with atherosclerosis (rs4142986, P = 0.017, OR = 1.434) was methylated and methylation of the risk allele correlated with decreased gene expression and increased atherosclerosis in human aorta. In summary, hypomethylation of COL15A1 occurs during SMC proliferation and the consequent increased gene expression may impact SMC phenotype and atherosclerosis formation. Hypomethylated genes, such as COL15A1, provide evidence for concomitant epigenetic regulation and genetic susceptibility, and define a class of causal targets that sit at the intersection of genetic and epigenetic predisposition in the etiology of complex disease.
Collapse
|
36
|
Redmond EM, Hamm K, Cullen JP, Hatch E, Cahill PA, Morrow D. Inhibition of patched-1 prevents injury-induced neointimal hyperplasia. Arterioscler Thromb Vasc Biol 2013; 33:1960-4. [PMID: 23766265 DOI: 10.1161/atvbaha.113.301843] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To determine the role of patched receptor (Ptc)-1 in mediating pulsatile flow-induced changes in vascular smooth muscle cell growth and vascular remodeling. APPROACH AND RESULTS In vitro, human coronary arterial smooth muscle cells were exposed to normal or pathological low pulsatile flow conditions for 24 hours using a perfused transcapillary flow system. Low pulsatile flow increased vascular smooth muscle cell proliferation when compared with normal flow conditions. Inhibition of Ptc-1 by cyclopamine attenuated low flow-induced increases in Notch expression while concomitantly decreasing human coronary arterial smooth muscle cell growth to that similar under normal flow conditions. In vivo, ligation injury-induced low flow increased vascular smooth muscle cell growth and vascular remodeling, while increasing Ptc-1/Notch expression. Perivascular delivery of Ptc-1 small interfering RNA by pluronic gel inhibited the pathological low flow-induced increases in Ptc-1/Notch expression and markedly reduced the subsequent vascular remodeling. CONCLUSIONS These results suggest that pathological low flow stimulates smooth muscle cell growth in vitro and vascular remodeling in vivo via Ptc-1 regulation of Notch signaling.
Collapse
Affiliation(s)
- Eileen M Redmond
- Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
| | | | | | | | | | | |
Collapse
|
37
|
van Varik BJ, Rennenberg RJMW, Reutelingsperger CP, Kroon AA, de Leeuw PW, Schurgers LJ. Mechanisms of arterial remodeling: lessons from genetic diseases. Front Genet 2012; 3:290. [PMID: 23248645 PMCID: PMC3521155 DOI: 10.3389/fgene.2012.00290] [Citation(s) in RCA: 100] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2012] [Accepted: 11/23/2012] [Indexed: 12/27/2022] Open
Abstract
Vascular disease is still the leading cause of morbidity and mortality in the Western world, and the primary cause of myocardial infarction, stroke, and ischemia. The biology of vascular disease is complex and still poorly understood in terms of causes and consequences. Vascular function is determined by structural and functional properties of the arterial vascular wall. Arterial stiffness, that is a pathological alteration of the vascular wall, ultimately results in target-organ damage and increased mortality. Arterial remodeling is accelerated under conditions that adversely affect the balance between arterial function and structure such as hypertension, atherosclerosis, diabetes mellitus, chronic kidney disease, inflammatory disease, lifestyle aspects (smoking), drugs (vitamin K antagonists), and genetic abnormalities [e.g., pseudoxanthoma elasticum (PXE), Marfan's disease]. The aim of this review is to provide an overview of the complex mechanisms and different factors that underlie arterial remodeling, learning from single gene defect diseases like PXE, and PXE-like, Marfan's disease and Keutel syndrome in vascular remodeling.
Collapse
Affiliation(s)
- Bernard J van Varik
- Department of Internal Medicine, Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht University Maastricht, Netherlands
| | | | | | | | | | | |
Collapse
|
38
|
Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2012; 34:719-28. [PMID: 23242196 DOI: 10.1093/eurheartj/ehs411] [Citation(s) in RCA: 694] [Impact Index Per Article: 57.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Although mortality rates from coronary heart disease in the western countries have declined in the last few decades, morbidity caused by this disease is increasing and a substantial number of patients still suffer acute coronary syndrome (ACS) and sudden cardiac death. Acute coronary syndrome occurs as a result of myocardial ischaemia and its manifestations include acute myocardial infarction and unstable angina. Culprit plaque morphology in these patients varies from thrombosis with or without coronary occlusion to sudden narrowing of the lumen from intraplaque haemorrhage. The coronary artery plaque morphologies primarily responsible for thrombosis are plaque rupture, and plaque erosion, with plaque rupture being the most common cause of acute myocardial infarction, especially in men. Autopsy data demonstrate that women <50 years of age more frequently have erosion, whereas in older women, the frequency of rupture increases with each decade. Ruptured plaques are associated with positive (expansive) remodelling and characterized by a large necrotic core and a thin fibrous cap that is disrupted and infiltrated by foamy macrophages. Plaque erosion lesions are often negatively remodelled with the plaque itself being rich in smooth muscle cells and proteoglycans with minimal to absence of inflammation. Plaque haemorrhage may expand the plaque rapidly, leading to the development of unstable angina. Plaque haemorrhage may occur from plaque rupture (fissure) or from neovascularization (angiogenesis). Atherosclerosis is now recognized as an inflammatory disease with macrophages and T-lymphocytes playing a dominant role. Recently at least two subtypes of macrophages have been identified. M1 is a pro-inflammatory macrophage while M2 seems to play a role in dampening inflammation and promoting tissue repair. A third type of macrophage, termed by us as haemoglobin associated macrophage or M(Hb) which is observed at site of haemorrhage also can be demonstrated in human atherosclerosis. In order to further our understanding of the specific biological events which trigger plaque instability and as well as to monitor the effects of novel anti-atherosclerotic therapies newer imaging modalities in vivo are needed.
Collapse
Affiliation(s)
- Erling Falk
- Aarhus University Hospital Skejby, Aarhus, Denmark
| | | | | | | | | |
Collapse
|
39
|
Validation of a new animal model of vulnerable plaques by intravascular optical coherence tomography in vivo. J Biomed Biotechnol 2012; 2012:469726. [PMID: 23093846 PMCID: PMC3470894 DOI: 10.1155/2012/469726] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2012] [Accepted: 08/31/2012] [Indexed: 11/17/2022] Open
Abstract
We aimed to establish a rabbit model of vulnerable plaques (VPs) with the morphology and component characteristics of human VPs and to evaluate the microstructural features of VPs in vivo using intravascular optical coherence tomography (OCT). Twelve rabbits underwent endothelial denudation of the carotid artery and consumed a 1% high-cholesterol diet (HCD). They were equally divided into two groups: group A (modified needle injury) and group B (balloon injury). OCT was undertaken thrice before injury as well as 1 h and 12 weeks after injury. The degree of acute artery injury after endothelial denudation was detected by OCT. Twelve weeks after injury, OCT showed that both groups generated VPs which had thin fibrous caps and a large lipid core, whereas plaques in group A had smaller lipid arcs (P < 0.0001). Histological findings demonstrated that a larger eccentricity index (EI) (P < 0.05) and greater infiltration of macrophages (P < 0.05) in group A than in group B. Qualitative and morphometric analyses of plaques showed a significant correlation between histological and OCT measurements. A combination of modified endothelial denudation and an HCD in rabbits produced more eccentric lesions similar to those seen in humans. These data suggest that OCT could be a useful tool for evaluation of the degree of injury and VPs in vivo.
Collapse
|
40
|
Srikanth S, Ambrose JA. Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI. Curr Cardiol Rev 2012; 8:168-76. [PMID: 22920487 PMCID: PMC3465820 DOI: 10.2174/157340312803217247] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2012] [Revised: 03/17/2012] [Accepted: 04/12/2012] [Indexed: 02/08/2023] Open
Abstract
Atherosclerosis is a systemic vascular pathology that is preceded by endothelial dysfunction. Vascular inflammation "fuels" atherosclerosis and creates the milieu for episodes of intravascular thromboses. Thrombotic events in the coronary vasculature may lead to asymptomatic progression of atherosclerosis or could manifest as acute coronary syndromes or even sudden cardiac death. Thrombus encountered in the setting of acute coronary syndromes has been correlated with acute complications during percutaneous coronary interventions such as no-reflow, acute coronary occlusion and long term complications such as stent thrombus. This article reviews the pathophysiology of coronary thrombogenesis and explores the complications associated with thrombus during coronary interventions.
Collapse
Affiliation(s)
- Sundararajan Srikanth
- Interventional Cardiology Fellow, UCSF Fresno, University of California San Francisco Chief of Cardiology, UCSF Fresno
| | - John A Ambrose
- Professor of Medicine, University of California San Francisco Chief of Cardiology, UCSF Fresno
| |
Collapse
|
41
|
Boyle JJ, Christou I, Iqbal MB, Nguyen AT, Leung VWY, Evans PC, Liu Y, Johns M, Kirkham P, Haskard DO. Solid-phase immunoglobulins IgG and IgM activate macrophages with solid-phase IgM acting via a novel scavenger receptor a pathway. THE AMERICAN JOURNAL OF PATHOLOGY 2012; 181:347-61. [PMID: 22658487 DOI: 10.1016/j.ajpath.2012.03.040] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2011] [Revised: 02/26/2012] [Accepted: 03/20/2012] [Indexed: 01/21/2023]
Abstract
IgG may accelerate atherosclerosis via ligation of proinflammatory Fcγ receptors; however, IgM is unable to ligate FcγR and is often considered vasculoprotective. IgM aggravates ischemia-reperfusion injury, and solid-phase deposits of pure IgM, as seen with IgM-secreting neoplasms, are well known clinically to provoke vascular inflammation. We therefore examined the molecular mechanisms by which immunoglobulins can aggravate vascular inflammation, such as in atherosclerosis. We compared the ability of fluid- and solid-phase immunoglobulins to activate macrophages. Solid-phase immunoglobulins initiated prothrombotic and proinflammatory functions in human macrophages, including NF-κB p65 activation, H(2)O(2) secretion, macrophage-induced apoptosis, and tissue factor expression. Responses to solid-phase IgG (but not to IgM) were blocked by neutralizing antibodies to CD16 (FcγRIII), consistent with its known role. Macrophages from mice deficient in macrophage scavenger receptor A (SR-A; CD204) had absent IgM binding and no activation by solid-phase IgM. RNA interference-mediated knockdown of SR-A in human macrophages suppressed activation by solid-phase IgM. IgM binding to SR-A was demonstrated by both co-immunoprecipitation studies and the binding of fluorescently labeled IgM to SR-A-transfected cells. Immunoglobulins on solid-phase particles around macrophages were found in human plaques, increased in ruptured plaques compared with stable ones. These observations indicate that solid-phase IgM and IgG can activate macrophages and destabilize vulnerable plaques. Solid-phase IgM activates macrophages via a novel SR-A pathway.
Collapse
Affiliation(s)
- Joseph J Boyle
- Vascular Sciences Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Alexander MR, Murgai M, Moehle CW, Owens GK. Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. Physiol Genomics 2012; 44:417-29. [PMID: 22318995 PMCID: PMC3339851 DOI: 10.1152/physiolgenomics.00160.2011] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Accepted: 01/17/2012] [Indexed: 12/14/2022] Open
Abstract
Smooth muscle cell (SMC) phenotypic modulation in atherosclerosis and in response to PDGF in vitro involves repression of differentiation marker genes and increases in SMC proliferation, migration, and matrix synthesis. However, SMCs within atherosclerotic plaques can also express a number of proinflammatory genes, and in cultured SMCs the inflammatory cytokine IL-1β represses SMC marker gene expression and induces inflammatory gene expression. Studies herein tested the hypothesis that IL-1β modulates SMC phenotype to a distinct inflammatory state relative to PDGF-DD. Genome-wide gene expression analysis of IL-1β- or PDGF-DD-treated SMCs revealed that although both stimuli repressed SMC differentiation marker gene expression, IL-1β distinctly induced expression of proinflammatory genes, while PDGF-DD primarily induced genes involved in cell proliferation. Promoters of inflammatory genes distinctly induced by IL-1β exhibited over-representation of NF-κB binding sites, and NF-κB inhibition in SMCs reduced IL-1β-induced upregulation of proinflammatory genes as well as repression of SMC differentiation marker genes. Interestingly, PDGF-DD-induced SMC marker gene repression was not NF-κB dependent. Finally, immunofluorescent staining of mouse atherosclerotic lesions revealed the presence of cells positive for the marker of an IL-1β-stimulated inflammatory SMC, chemokine (C-C motif) ligand 20 (CCL20), but not the PDGF-DD-induced gene, regulator of G protein signaling 17 (RGS17). Results demonstrate that IL-1β- but not PDGF-DD-induced phenotypic modulation of SMC is characterized by NF-κB-dependent activation of proinflammatory genes, suggesting the existence of a distinct inflammatory SMC phenotype. In addition, studies provide evidence for the possible utility of CCL20 and RGS17 as markers of inflammatory and proliferative state SMCs within atherosclerotic plaques in vivo.
Collapse
Affiliation(s)
- Matthew R Alexander
- Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA
| | | | | | | |
Collapse
|
43
|
Abstract
Smooth muscle cells (SMCs) possess remarkable phenotypic plasticity that allows rapid adaptation to fluctuating environmental cues, including during development and progression of vascular diseases such as atherosclerosis. Although much is known regarding factors and mechanisms that control SMC phenotypic plasticity in cultured cells, our knowledge of the mechanisms controlling SMC phenotypic switching in vivo is far from complete. Indeed, the lack of definitive SMC lineage-tracing studies in the context of atherosclerosis, and difficulties in identifying phenotypically modulated SMCs within lesions that have down-regulated typical SMC marker genes, and/or activated expression of markers of alternative cell types including macrophages, raise major questions regarding the contributions of SMCs at all stages of atherogenesis. The goal of this review is to rigorously evaluate the current state of our knowledge regarding possible phenotypes exhibited by SMCs within atherosclerotic lesions and the factors and mechanisms that may control these phenotypic transitions.
Collapse
Affiliation(s)
- Delphine Gomez
- Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, 415 Lane Road, PO Box 801394, Room 1322 Medical Research Building 5, Charlottesville, VA 22908, USA
| | | |
Collapse
|
44
|
Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2011; 122:70-9. [PMID: 22201681 DOI: 10.1172/jci43713] [Citation(s) in RCA: 168] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Accepted: 10/19/2011] [Indexed: 12/13/2022] Open
Abstract
Clinical complications of atherosclerosis arise primarily as a result of luminal obstruction due to atherosclerotic plaque growth, with inadequate outward vessel remodeling and plaque destabilization leading to rupture. IL-1 is a proinflammatory cytokine that promotes atherogenesis in animal models, but its role in plaque destabilization and outward vessel remodeling is unclear. The studies presented herein show that advanced atherosclerotic plaques in mice lacking both IL-1 receptor type I and apolipoprotein E (Il1r1⁻/⁻Apoe⁻/⁻ mice) unexpectedly exhibited multiple features of plaque instability as compared with those of Il1r1⁺/⁺Apoe⁻/⁻ mice. These features included reduced plaque SMC content and coverage, reduced plaque collagen content, and increased intraplaque hemorrhage. In addition, the brachiocephalic arteries of Il1r1⁻/⁻Apoe⁻/⁻ mice exhibited no difference in plaque size, but reduced vessel area and lumen size relative to controls, demonstrating a reduction in outward vessel remodeling. Interestingly, expression of MMP3 was dramatically reduced within the plaque and vessel wall of Il1r1⁻/⁻Apoe⁻/⁻ mice, and Mmp3⁻/⁻Apoe⁻/⁻ mice showed defective outward vessel remodeling compared with controls. In addition, MMP3 was required for IL-1-induced SMC invasion of Matrigel in vitro. Taken together, these results show that IL-1 signaling plays a surprising dual protective role in advanced atherosclerosis by promoting outward vessel remodeling and enhancing features of plaque stability, at least in part through MMP3-dependent mechanisms.
Collapse
Affiliation(s)
- Matthew R Alexander
- Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
| | | | | | | | | | | | | |
Collapse
|
45
|
TNF-α response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73. Cell Death Differ 2011; 19:274-83. [PMID: 21738216 DOI: 10.1038/cdd.2011.93] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Atherosclerosis involves a specialized inflammatory process regulated by an intricate network of cytokine and chemokine signaling. Atherosclerotic lesions lead to the release of cytokines that can have multiple affects on various vascular cell functions either promoting lesion expansion or alternatively retard progression. Tumor necrosis factor-α (TNF-α) is one such cytokine that can activate both cell survival and cell death mechanisms simultaneously. Here we show that TNF-α induces apoptosis in human aortic endothelial cells (HAECs), while it promotes the proliferation of vascular smooth muscle cells (VSMCs). Both events involved the activation of the Rb-E2F1 transcriptional regulatory pathway. Stimulation of HAECs with TNF-α led to an increased expression of p73 protein and a reduction in the levels of p53. This involved apoptosis signal-regulating kinase 1 (ASK1)- mediated inactivation of Rb and its dissociation from the p73 promoter. In contrast, TNF-α stimulation of VSMCs enhanced the association of E2F1 with proliferative promoters like thymidylate synthase and cdc25A, while Rb was dissociated. ASK1 kinase has a critical role in the apoptotic process, as its depletion or dissociation from Rb reduced TNF-α-induced apoptosis. These results show that the cytokine TNF-α can elicit diametrically opposite responses in vascular endothelial cells and VSMCs, utilizing the Rb-E2F pathway.
Collapse
|
46
|
Affiliation(s)
- Sophie E. P. New
- Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital
| | - Elena Aikawa
- Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital
| |
Collapse
|
47
|
Costales P, Aledo R, Vérnia S, Das A, Shah V, Casado M, Badimon L, Llorente-Cortés V. Selective role of sterol regulatory element binding protein isoforms in aggregated LDL-induced vascular low density lipoprotein receptor-related protein-1 expression. Atherosclerosis 2010; 213:458-68. [DOI: 10.1016/j.atherosclerosis.2010.09.034] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2010] [Revised: 09/15/2010] [Accepted: 09/29/2010] [Indexed: 11/24/2022]
|
48
|
Daniel JM, Sedding DG. Circulating smooth muscle progenitor cells in arterial remodeling. J Mol Cell Cardiol 2010; 50:273-9. [PMID: 21047514 DOI: 10.1016/j.yjmcc.2010.10.030] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2010] [Revised: 10/17/2010] [Accepted: 10/26/2010] [Indexed: 10/18/2022]
Abstract
The proliferation and migration of vascular smooth muscle cells (SMCs) from the media toward the intimal layer are key components in vascular proliferative diseases. In addition, the differentiation of circulating bone marrow-derived mononuclear cells (BMMCs) into SMCs has been described to contribute to lesion progression in experimental models of atherosclerosis, transplant arteriosclerosis, and neointima formation. In vitro, CD14(+) BMMCs from peripheral blood acquire a spindle-shaped phenotype and express specific SMC markers in response to platelet-derived growth factor-BB. However, the 'trans-differentiation' capacity of BMMCs into definitive SMCs in vivo remains a highly controversial issue. Whereas SMCs within atherosclerotic plaques have been demonstrated to be exclusively of local origin, more severe injury models have shown a wide diversity of SMCs or smooth muscle-like cells derived from BMMCs. In hindsight, these discrepancies may be attributed to methodological differences, e.g., the use of high-resolution microscopy or the specificity of the SMC marker proteins. In fact, the analysis of mouse strains that express marker genes under the control of a highly specific smooth muscle-myosin heavy chain (SM-MHC) promoter and a time-course analysis on the dynamic process of neointima formation have recently shown that BMMCs temporarily express α-smooth muscle actin, not SM-MHC. Additionally, BM-derived cells disappear from the neointimal lesion after the inflammatory response to the injury has subsided. Although CD14(+)/CD68(+) have important paracrine effects on arterial lesion progression, BMMCs account for more of the 'SMC-like macrophages' than the highly 'trans-differentiated' and definitive SMCs in vivo. This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".
Collapse
Affiliation(s)
- Jan-Marcus Daniel
- Department of Cardiology, Justus-Liebig-University, Giessen, Germany
| | | |
Collapse
|
49
|
Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, Eguchi K, Furuya A, Kuro-o M, Sata M, Nagai R. Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation 2010; 122:2048-57. [PMID: 21041690 DOI: 10.1161/circulationaha.110.965202] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND It has been proposed that bone marrow-derived cells infiltrate the neointima, where they differentiate into smooth muscle (SM) cells; however, technical limitations have hindered clear identification of the lineages of bone marrow-derived "SM cell-like" cells. METHODS AND RESULTS Using a specific antibody against the definitive SM cell lineage marker SM myosin heavy chain (SM-MHC) and mouse lines in which reporter genes were driven by regulatory programs for either SM-MHC or SM α-actin, we demonstrated that although some bone marrow-derived cells express SM α-actin in the wire injury-induced neointima, those cells did not express SM-MHC, even 30 weeks after injury. Likewise, no SM-MHC(+) bone marrow-derived cells were found in vascular lesions in apolipoprotein E(-/-)mice or in a heart transplantation vasculopathy model. Instead, the majority of bone marrow-derived SM α-actin(+) cells were also CD115(+)CD11b(+)F4/80(+)Ly-6C(+), which is the surface phenotype of inflammatory monocytes. Moreover, adoptively transferred CD11b(+)Ly-6C(+) bone marrow cells expressed SM α-actin in the injured artery. Expression of inflammation-related genes was significantly higher in neointimal subregions rich in bone marrow-derived SM α-actin(+) cells than in other regions. CONCLUSIONS It appears that bone marrow-derived SM α-actin(+) cells are of monocyte/macrophage lineage and are involved in vascular remodeling. It is very unlikely that these cells acquire the definitive SM cell lineage.
Collapse
Affiliation(s)
- Hiroshi Iwata
- Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Seo D, Goldschmidt-Clermont P, Goldschidt-Clermont P, Velazquez O, Beecham G. Genomics of premature atherosclerotic vascular disease. Curr Atheroscler Rep 2010; 12:187-93. [PMID: 20425258 DOI: 10.1007/s11883-010-0104-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Atherosclerotic vascular disease is a systemic process with a common pathophysiology but with different disease manifestations depending on the vascular site. Over the past two decades, significant efforts have gone toward determining the genomic factors contributing to atherosclerotic vascular disease. Substantial information has been generated regarding the genomics of atherosclerotic coronary heart disease, and recently, several genomic analyses have looked at the cerebrovascular and peripheral vascular beds. This article reviews genomic investigations of atherosclerotic vascular disease in the coronary, cerebrovascular, and peripheral arteries. In this review, we have tried to restrict the discussion to studies of premature atherosclerosis, particularly those using non-biased genomic techniques.
Collapse
Affiliation(s)
- David Seo
- University of Miami Miller School of Medicine, 1501 NW 10th Ave, 809 Biomedical Research Building, Miami, FL 33136, USA.
| | | | | | | | | |
Collapse
|